Loading...
Market
What will be TERN-601's mean weight loss in Phase 2 trials?
2
Resolution / Starting Odds
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Terns Pharmaceuticals official announcements, clinical trial results publications
Story
Terns Pharmaceuticals Stock Soars 10% After Positive Phase 1 Trial Results Showing 5.5% Weight Loss
Sep 9, 2024, 11:09 AM
Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo-adjusted weight loss. The study also reported the absence of treatment-related dose interruptions, reductions, or discontinuations, with mostly mild adverse events, despite aggressive titration to high doses. Following this announcement, Terns Pharmaceuticals' stock soared by 10%.
View original story
Similar markets
Mean weight loss < 5% • 25%
Mean weight loss 5% to 7% • 25%
Mean weight loss 7% to 9% • 25%
Mean weight loss > 9% • 25%
Less than 5% weight loss • 25%
5% to 10% weight loss • 25%
10% to 15% weight loss • 25%
More than 15% weight loss • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%
Less than 15% • 25%
15% to 19.9% • 25%
20% to 24.9% • 25%
25% or more • 25%